A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)



Status:Completed
Conditions:Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:12 - 16
Updated:10/6/2017
Start Date:April 2012
End Date:February 2015

Use our guide to learn which trials are right for you!

A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)

A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.


Inclusion Criteria:

- Parent or legal guardian is able to provide written informed consent and patient is
able to provide written assent if appropriate.

- Male and female adolescents aged 12 to 16 years at the time of enrollment.

- Diagnosed with JIA, including all the International League of Associations for
Rheumatology JIA subtypes: oligoarthritis, polyarthritis (both rheumatoid factor [RF]+
and RF-), psoriatic arthritis, enthesitis-related arthritis, undifferentiated
arthritis, and systemic arthritis.

- Based upon investigator judgment, it is determined appropriate for the patient to
undergo 6 months of continuous treatment with VIMOVO.

- Body weight > 31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass
index for age.

Exclusion Criteria:

- In systemic JIA patients, presence of systemic features (ie, fever, rheumatoid rash,
serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to
start of study drug.

- Currently taking (ie, within 4 weeks prior to start of drug) naproxen > 20 mg/kg/day
or > 1000 mg total daily dose.

- Hemoglobin ≤ 8.5 g/dL.

- Individuals who have cardiovascular or cerebrovascular disease, based on history or
risk factors.

- Any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other
medical conditions indicated by medical/surgical history, physical, or laboratory
examination that might put the patient at greater risk during the study.
We found this trial at
17
sites
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
?
mi
from
Washington, D.C.,
Click here to add this to my saved trials
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials